E
XORTX Therapeutics Inc. XRTX
$3.27 $0.23427.70%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
E
Sell 12/11/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D- on 12/11/2023 due to a decline in the volatility index and total return index.
D
Sell 11/24/2023Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D- from E+ on 11/24/2023 due to an increase in the volatility index.
E
Sell 11/17/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D- on 11/17/2023 due to a decline in the volatility index and total return index.
D
Sell 11/1/2023Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D- from E+ on 11/1/2023 due to an increase in the volatility index.
E
Sell 10/13/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D- on 10/13/2023 due to a decline in the volatility index.
D
Sell 8/22/2023Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D- from E+ on 8/22/2023 due to an increase in the growth index and volatility index. Operating cash flow increased 30.32% from -$2.48M to -$1.73M, EBIT increased 11.23% from -$1.68M to -$1.49M, and earnings per share increased from -$0.1055 to -$0.094.
E
Sell 8/3/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D- on 8/3/2023 due to a decline in the volatility index and growth index.
D
Sell 7/18/2023Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D- from E+ on 7/18/2023 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 6.94 to 13.25, operating cash flow increased 34.62% from -$3.8M to -$2.48M, and EBIT increased 31.42% from -$2.45M to -$1.68M.
E
Sell 4/10/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D on 4/10/2023 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 299.4% from -$951.2 to -$3.8M, net income declined 79.53% from -$1.2M to -$2.15M, and earnings per share declined from -$0.0922 to -$0.1503.
D
Sell 3/24/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D from D+ on 3/24/2023 due to a decline in the volatility index and total return index.
D
Sell 3/8/2023Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D+ from D on 3/8/2023 due to an increase in the volatility index and valuation index.
D
Sell 2/16/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D from D+ on 2/16/2023 due to a decline in the volatility index.
D
Sell 1/31/2023Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D+ from D on 1/31/2023 due to an increase in the volatility index and valuation index.
D
Sell 1/11/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D from D+ on 1/11/2023 due to a decline in the total return index, volatility index and efficiency index.
D
Sell 12/6/2022Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D+ from C- on 12/6/2022 due to a decline in the volatility index, total return index and valuation index.
C
Hold 11/17/2022Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to C- from D on 11/17/2022 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 49.47% from -$1.88M to -$950.6, EBIT increased 10.45% from -$2.21M to -$1.98M, and earnings per share increased from -$0.0954 to -$0.0921.
D
Sell 11/11/2022Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D from D- on 11/11/2022 due to an increase in the growth index, solvency index and valuation index. Earnings per share increased from -$0.2081 to -$0.0954, operating cash flow increased 24.83% from -$2.5M to -$1.88M, and EBIT increased 15.42% from -$2.61M to -$2.21M.
D
Sell 8/30/2022Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D- from D on 8/30/2022 due to a decline in the total return index.
D
Sell 8/15/2022Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D from D- on 8/15/2022 due to an increase in the volatility index.
D
Sell 5/25/2022Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D- from D on 5/25/2022 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 26.97 to 18.3.
D
Sell 5/5/2022Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and valuation index.
D
Sell 4/20/2022Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 5,018.76% from -$61.3 to -$3.14M, and EBIT declined 432.22% from -$197.7 to -$1.05M.
D
Sell 12/20/2021Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D from D+ on 12/20/2021 due to a large decline in the total return index and volatility index.
D
Sell 12/2/2021Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D+ from D on 12/2/2021 due to a large increase in the total return index and valuation index.
D
Sell 11/23/2021Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell 11/8/2021Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D- from D on 11/08/2021.
D
Sell 2/2/2021Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to D from D- on 2/2/2021 due to a large increase in the total return index and volatility index.
D
Sell 12/23/2020Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to D- from E+ on 12/23/2020 due to an increase in the total return index and volatility index.
E
Sell 12/8/2020Downgrade
XORTX Therapeutics Inc. (XRTXF) was downgraded to E+ from D- on 12/8/2020 due to a large decline in the total return index and volatility index.
D
Sell 10/26/2020Downgrade
XORTX Therapeutics Inc. (XRTXF) was downgraded to D- from D on 10/26/2020 due to a decline in the volatility index.
D
Sell 9/17/2020Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to D from D- on 9/17/2020 due to an increase in the total return index and volatility index.
D
Sell 9/2/2020Downgrade
XORTX Therapeutics Inc. (XRTXF) was downgraded to D- from D on 9/2/2020 due to a decline in the valuation index and growth index. Earnings per share declined from -$0.0004 to -$0.0072, and EBIT declined 161.67% from -$87.4 to -$228.7.
D
Sell 5/18/2020Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to D from D- on 5/18/2020 due to an increase in the volatility index, total return index and growth index.
D
Sell 4/30/2020Downgrade
XORTX Therapeutics Inc. (XRTXF) was downgraded to D- from D on 4/30/2020 due to a major decline in the solvency index and growth index. Operating cash flow declined 919.59% from $9.7 to -$79.5, debt to equity increased from -0.49 to -0.24, and the quick ratio declined from 0.11 to 0.06.
D
Sell 12/2/2019Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to D from D- on 12/2/2019 due to an increase in the valuation index, efficiency index and volatility index. Net income increased 14.03% from -$116.2 to -$99.9.
D
Sell 8/1/2019Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to D- from E on 8/1/2019 due to an increase in the valuation index.
E
Sell 7/15/2019Downgrade
XORTX Therapeutics Inc. (XRTXF) was downgraded to E from E+ on 7/15/2019 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.14 to 0.28, and the quick ratio declined from 0.32 to 0.19.
E
Sell 5/1/2019Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to E+ from E on 5/1/2019 due to a noticeable increase in the total return index, volatility index and growth index. EBIT increased 57.18% from -$210.2 to -$90, earnings per share increased from -$0.0037 to -$0.0018, and operating cash flow increased 38.15% from -$152.3 to -$94.2.
E
Sell 3/4/2019Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to E from E- on 3/4/2019 due to an increase in the volatility index and total return index.
E
Sell 2/26/2019None
XORTX Therapeutics Inc. (XRTX) was downgraded to E- from U on 02/26/2019.
Weiss Ratings